PROGRESS INNOVATION





MISSION

To fund research with the highest probability of preventing, slowing or reversing Alzheimer's disease.


curealz.org

2016 ANNUAL REPORT

Message from the Co-Chairmen of Cure Alzheimer's Fund	2
By the Numbers	6
Message from the President	9
2016 Fundraising	10
2016 Financials	11
2016 Highlights	12
Thank You to Our Heroes	13
In Honor and in Memory	14
Join Our Effort	15
Poord of Directors & Administration	16

Message from the Co-Chairmen of Cure Alzheimer's Fund

Jeff Morby and Henry McCance



We think these [5] leadership roles make us unique among Alzheimer's disease research groups, help explain our momentum, and are important to review with you.

Dear Friends,

We are pleased to report that in 2016, our cumulative committed research funding exceeded \$50 million, and as of this writing, that number already has grown to \$60 million. In 2016, we granted a record \$13.5 million for 56 projects, an increase of 34 percent from 2015. The 2016 funding was provided by \$15.6 million in donations from 15,000 donors, our 12th record fundraising year and an increase of 33 percent from 2015.

OUR LEADERSHIP ROLES

In last year's chairman's letter, Jeff Morby summarized five leadership roles that Cure Alzheimer's Fund (CureAlz) has carried out within the field. We think these leadership roles make us unique among Alzheimer's disease research groups, help explain our momentum, and are important to review with you.

First: Leadership in the Genetics of Alzheimer's Disease. From the founding of CureAlz, we have emphasized the importance of genetics to Alzheimer's research. Our goal has been to identify all risk genes, use those genes to identify disease mechanisms, and pursue potential therapies based on the knowledge gained from AD genes.

In 2005, there were only four known Alzheimer's genes, representing about 30 percent of the genetic profile of the disease. Rudy Tanzi had co-discovered three of those four genes. Later, as head of our Alzheimer's Genome Project™ (AGP), he discovered five new AD genes; the discovery was named one of the "Top 10 Medical Breakthroughs" in 2008 by TIME magazine. Since then, one of those five, CD33, has become the second-biggest drug target for Alzheimer's in the biopharma industry (the first being the amyloid precursor protein discovered by Rudy in 1987). In 2013, we were the first research organization to use "whole genome sequencing" to sequence the entire DNA of more than 1,500 individuals from AD families, and this has led to the discovery of more than 100 new Alzheimer's candidate genes.

We now have the most comprehensive Alzheimer's genomics database in the world.

We now have the most comprehensive Alzheimer's genomics database in the world. It is being used to find the variants in the candidate genes that underlie biological risk for the disease, the results of which provide the underlying data for the Genes to Therapies $^{\text{TM}}$ (G2T) program. In that program we study how the newly identified Alzheimer's gene variants cause AD and how we can design therapeutic leads to prevent them from doing so.

More than two-thirds of the 5.4 million
Americans living with Alzheimer's are women.
In 2016, CureAlz and the Rotary International
Foundation co-funded a research project
to analyze databases of Alzheimer's family
genomes and, for the first time, identify gene variants that
impact risk differently for women than for men. We already
have found several new genes involved with inflammation in
the brain that influence risk differently in females versus males,
and expect to find additional differences in 2017.

Second: Leadership in the Creation of Advanced Research Tools. In order to study the new AD risk gene variants identified in the AGP, a large number of new mouse models of newly discovered AD genes are being created as part of G2T. Our scientists actively are using these mice "tools" to better understand different disease processes and test new therapies. In addition to the mouse models, the new Alzheimer's genes and variants also are being studied using a unique new analytical tool developed by Rudy and Doo Yeon Kim in 2015, dubbed "Alzheimer's in a Dish" (ADiD). The New York Times referred to it as "a giant step forward" for the field.

ADiD uses human stem cells to grow Alzheimer's nerve cells and see them, which develop within an artificial mini-brain in a Petri dish gel that resembles the consistency of the brain. For the first time, this system is allowing both amyloid plaque and tau tangle pathology to be created and analyzed in a Petri dish. The system has been shared openly with the Alzheimer's field and is potentially revolutionizing Alzheimer's drug discovery; it now allows research studies to be carried

out significantly faster and cheaper than with mice. Using this system and high-throughput screening of literally thousands of drugs, G2T has led to the discovery of nearly 50 known drugs and natural products that potentially reduce Alzheimer's pathology. These drugs now are being analyzed for repurposing as Alzheimer's drugs, with the expectation that some will become candidates for human trials.

Our researchers continue to enhance the diagnostic capabilities of ADiD by adding inflammatory and blood-brain barrier genes to the ADiD mini-brain. Both inflammation and blood-brain deficiencies are major contributors to Alzheimer's disease, and ADiD already is providing us with new insights. Furthermore, ADiD has proven to be a research tool of analysis for a number of different neurological diseases, such as Parkinson's and ALS. Because of its analytical potential for the scientific community, in April 2017 CureAlz sponsored a highly successful symposium at the Alzheimer's Disease/Parkinson's Diseases Congress (ADPD) in Vienna, which updated more than 1,000 scientists on the latest advances in the ADiD model, and its use and results in drug screening.

Third: Leadership in the Development of Effective Forms of Scientific Collaboration.

Our Research Consortium and Scientific Advisory Board members are some of the world's most brilliant Alzheimer's researchers. In 2016, we added three exceptional scientists to our Research Consortium: Ben Barres of Stanford University, Bart De Strooper of the UK Dementia Research Institute, and Nancy Ip of the Hong Kong University of Science and Technology. Apart from their capabilities, what truly distinguishes all of the scientists involved with our organization is their willingness to collaborate. All of them have developed in conjunction with CureAlz an atmosphere of trust and cooperation. All are willing to share their unpublished data and insights, and to participate in quarterly brainstorming sessions focused on attacking the disease in new and creative ways. Additionally, they are guided in their research decisions by the CureAlz Roadmap, a jointly shared overall research strategy, which is updated as new scientific insights are attained.

In 2016, Rob Moir and Rudy Tanzi published a new paper on the "Anti-Microbial Hypothesis," which *The New York Times* described as

"provocative new research."

Fourth: Conceptual Leadership in the Field of **Alzheimer's Research.** Our emphasis on genomics, translational drug discovery, the development of new tools and databases, and our collaborative approach to scientific exploration, has allowed CureAlz and its researchers to conceptualize a comprehensive model of Alzheimer's disease that has led to a generally accepted scientific consensus about how Alzheimer's disease originates and creates a vicious cycle of abeta peptide accumulation, tangle formation, nerve cell death and inflammation, leading to ever-accelerating nerve cell death. This model leads to three basic strategies for medical intervention (intervention points), around which we have organized our research: 1) early-phase intervention, inhibiting abeta peptide deposition and/or clearing it from the brain; 2) mid-phase intervention, preventing the formation and spreading of tau tangles; and 3) late-phase intervention, fighting inflammation and slowing down or stopping the disease process.

In 2016, Rob Moir and Rudy Tanzi published a new paper on the "Anti-Microbial Hypothesis," which The New York Times described as "provocative new research." This revolutionary hypothesis about the underlying cause of Alzheimer's disease shows that abeta, the peptide that forms plaque in the brain, is also a component of the brain's innate immune system, the system that protects the brain from pathogens. Abeta traps and kills pathogens when they enter the brain, essential for the protection of the brain. However, too much of this activity, resulting from genetic or other defects, may cause the brain to overproduce, or fail to clear, abeta, thereby starting the vicious cycle of the disease. This radical new view has major implications for drug discovery.

As new discoveries are made we adjust our research strategy (the Roadmap), which defines our priorities. Recently it has been found that the human gut microbiome has the capacity to influence how our genes code for a variety of Alzheimer's-related phenomena, including brain inflammation. Accordingly, in 2016 we funded Sam Sisodia of the University of Chicago to investigate the link between the gut microbiome and Alzheimer's disease; that investigation is continuing. Last year, Sam published an important paper showing that the gut microbiome controls plaque formation in AD mouse models.

Fifth: Leadership in Foundation Management (Venture Philanthropy). Many of the CureAlz founders are former venture capitalists. The founders and directors have, over time, personally contributed more than \$28 million to the foundation. The founders and directors pay all operating expenses of the foundation, so that 100 percent of any contribution from our generous donors goes directly into research. We want a cure or preventive measures identified as soon as possible, and we manage CureAlz with this goal. The management processes we have set up, which we call "venture philanthropy," distinguish us as risk takers, fast decision makers and strategists. We proactively recruit the best researchers, fund them with no bureaucracy, challenge them for high-risk/high-reward projects and insist they collaborate. This venture philanthropy approach is one of the reasons for our significant momentum and successes, which have resulted in our being awarded—for the last five consecutive years—a four-star rating by Charity Navigator, including this last year under its new rating system a prestigious Perfect 100 Percent score, given to only 50 of 8,000 charities in the United States.

GOING FORWARD

While we are proud of these leadership roles we have achieved, we always are seeking to improve, and to make our research grants more impactful. To that end, during 2016 we conducted a detailed strategic review process, performed by a third-party strategy consultant. One of the recommendations adopted by the board from that process was to fund larger initiatives, involving multi-institutional consortia, to more deeply engage our leading researchers to holistically address strategic research themes. In that vein, we have formed our first consortium, CIRCUITS, a collaboration of nine research leaders from eight institutions, to use cuttingedge functional genomics, including epigenetic analysis and computational biostatistical tools, to model cellular pathways and gene interactions too complex to have been captured by past genetic analysis of protein production alone.

The dataset of AD-relevant genes, variants, cell types and regulators produced will be made available to the entire field, providing a powerful new data-driven model to accelerate identification of potential points for therapeutic intervention. A second consortium focused on the APOE gene is in the process of being formed, as is a third, which is focused on the role of the brain's immune response in Alzheimer's disease. At the same time, we will continue to fund smaller "high-risk" and "proof-of-concept" grants, which have been such productive sources of our progress to date.

As we enter 2017, we acknowledge that Alzheimer's disease increasingly has been in the news. On the positive side, awareness of AD in the public continues to increase, and research funding was a presidential campaign issue. On the negative side, several recent pharmaceutical-driven AD trials failed, and the initial 2017 U.S. budget proposal calls for cuts in National Institutes of Health research funding. All of this makes our focus on investigating the fundamental causes of Alzheimer's disease even more important. We must have a comprehensive understanding of this disease to develop the successful therapies of the future. In the nearer term, we have two potential therapies entering clinical trials in 2017. One is a gamma secretase modulator, which has the potential of being a "statin" for AD. The second, Amylyx, is a medicine developed to protect neurons from cell damage, and is potentially useful for both ALS and AD.

All of the above would not have been possible without your generous support. We are forever grateful to each and every one of our donors, to our wonderful researchers—who are more excited with their progress than ever—and to our dedicated staff. We will not rest until a set of effective therapies rids this planet of this dreaded disease; with your help, we will succeed.

Very Best Wishes,

Jeffrey L. Morby Henry F. McCance Co-Chairmen and Co-Founders

We have formed our first consortium, CIRCUITS, a collaboration of nine research leaders from eight institutions, to use cutting-edge functional genomics, including epigenetic analysis and computational biostatistical tools, to model cellular pathways and gene interactions too complex to have been captured by past genetic analysis of protein production alone.

BY THE NUMBERS

Cure Alzheimer's Fund is supporting research and making an impact around the world.

33%

Increase from 2015 in Donations

In 2016

15,347 Gifts

\$15.6
Million

Donations Received

Since Inception Funded Research Projects

The searchers Funded

100 PERCENT

Perfect Score Awarded to Cure Alzheimer's Fund by Charity Navigator

34%

Increase from 2015 in Research Grants
Distributed



Funded Research Projects

58Researchers Funded

\$13.5
Million

Research Grants
Distributed

宣225

Published Papers

12,000

The number of times our researchers' papers have been cited

\$50 Million

Total Research Grants
Distributed

Cure Alzheimer's Fund is honored to have received the prestigious designation of

TOTAL DE LA COLONIA DE LA COLO

by the charity watchdog organization

CHARITY NAVIGATOR.

Awarded to only 50 of 8,000 charities in the United States, the award is based on excellence in financial management and transparency.

This award is in addition to the rating of 4 stars received for the sixth consecutive time.





Message from the President

Tim Armour, President and CEO, Cure Alzheimer's Fund

Dear Friends,

The momentum continues from our sensational 2015 year of growth in the amount of money our board and donors were able to commit to research. In 2016 we "invested" an impressive 35% growth in funding of innovative research (\$13.5 million in 2016); and experienced a 33% growth in contributions from the previous year (\$15.6 million in 2016).

Our co-chairs, Jeff Morby and Henry McCance, have documented our research leadership elsewhere in this report highlighting the impact of the combined efforts of founders, board members, staff, donors and researchers. A full description of the research we funded in 2016 is available in our Research Annual and online at www.curealz.org/research-annual.

We are deeply grateful to the generous donors who have made this continuing success possible. In 2016 alone, we enjoyed the support of more than 11,000 donors to fund 56 research grants with 58 researchers from 32 institutions in the United States and abroad.

Our continued success is the result of adherence to a few basic principles.

1. We seek and focus on only the best science to find the fastest and most effective ways to lead to treatments of Alzheimer's disease. We believe that there can be no "cure" without understanding the "cause," and we are committed to contributing knowledge to the field about the pathology of the disease in order to hasten the development of effective therapies.

- 2. We heed the call of the science; we don't direct it. We believe in identifying the best minds in Alzheimer's research, and providing them with the tools to follow their best judgment to unravel the mysteries of Alzheimer's disease.
- 3. We believe in results over process. While upholding the highest standards of scientific integrity among the researchers we fund, we work hard to eliminate needless and cumbersome bureaucracy and process that slow research progress.
- 4. Supporting point No. 3, we allow for idiosyncratic organization and process within our foundation and among our researchers. We do not strive to be like every other organization, but to organize ourselves and allow our researchers to go about their work in ways we all together believe will produce the best results.
- We embrace risk. We are not risk seekers, but we eschew incrementalism and cautious improvement in favor of bold breakthroughs.

The more than \$50 million in research grants awarded by Cure Alzheimer's Fund has brought us all closer to relieving the suffering of Alzheimer's disease. We are not there yet—we have much very hard work left to do, and we need all the help we can get.

To all those who have brought us this far, thank you. And to those who will join us, welcome.

Sincerely,

Tim

Funding Our Vital Research

The Cure Alzheimer's Fund Board pays 100 percent of all of our operating expenses, making it possible for 100 percent of all donations to go directly to research.

CureAlz keeps all funds in cash equivalents.
Because the objective is to move money from donors to research as quickly as possible, CureAlz has no endowment or investment fund.

CureAlz funds projects approved by its Scientific Advisory Board. While proposal approval is streamlined to facilitate a focus on results rather than process, scientific integrity is CureAlz's top concern.


CureAlz has a history of "clean" audits. CureAlz's IRS Form 990 and audited financial statements are available online at curealz.org.


In 2016, CureAlz was awarded its 6th consecutive 4-star rating from Charity Navigator, the country's largest evaluator of charities. Four stars is the highest possible rating and is awarded to organizations that display sound fiscal management, accountability and transparency.

In 2016, Charity Navigator awarded CureAlz a perfect 100 point overall score. Less than 1 percent of the thousands of charities rated by Charity Navigator have earned perfect scores.

2016 FUNDRAISING

In 2016, Cure Alzheimer's Fund received 15,347 gifts—from individuals, corporations and foundations—totaling \$15,654,643 in cash and in-kind revenues.





Cumulative contributions from inception given by the Founders and Board total \$28,650,875. Cumulative expenses from inception paid by the Founders and Board total \$15,072,838.

2016 FINANCIALS (Year ended Dec. 31, 2016)

UNRESTRICTED NET ASSETS

NET ASSETS, beginning of year

NET ASSETS, end of year

Statement of Financial Position

ASSETS	
Cash and cash equivalents	\$9,080,684
Restricted cash, documentary project funds (temporarily restricted)	83,336
Contributions receivable and undeposited funds	579,334
Pledges receivable (temporarily restricted)	2,518,491
Deposits – donor-advised funds	9,102
Equipment, net	50,909
Other assets	141,354
TOTAL ASSETS	12,463,210
LIABILITIES AND NET ASSETS	
LIABILITIES	
Accounts payable and accrued expenses	563,695
Total liabilities	563,695
NET ASSETS	
Unrestricted	8,710,240
Temporarily restricted	
Pledges receivable	2,518,491
Documentary program project	83,336
Personnel	136,532
Research in African American Population	450,916
Total temporarily restricted	3,189,275
Total net assets	11,899,515
TOTAL LIABILITIES AND NET ASSETS	\$12,463,210

Statement of Activities

UNRESTRICTED NET ASSETS	
REVENUE AND OTHER SUPPORT	
Contributions	\$14,277,676
Net assets released from restrictions (pledges)	750,000
Donated services & equipment	39,666
Investment income	611
Realized (loss) gain in sale of stocks	(64,407)
Unrealized gain on donor advised funds	(113)
Other income	90
Net assets released from restrictions (documentary project)	11,679
TOTAL REVENUE AND OTHER SUPPORT	15,015,202
EXPENDITURES	
Program expenses:	
Research distributions	13,455,939
Documentary program project expenses	11,679
Operating program expenses	1,690,743
Total program expenses	15,158,361
Management and general	708,355
Fundraising	662,484
TOTAL EXPENDITURES	16,529,200
(DECREASE) INCREASE IN UNRESTRICTED NET ASSETS	(1,513,998)
TEMPORARILY RESTRICTED NET ASSETS	
Contributions	587,448
Pledge contributions, net	1,329,838
Net assets released from restrictions	(761,679)
(DECREASE) INCREASE IN TEMPORARILY RESTRICTED NET ASSETS	1,155,607
CHANGES IN NET ASSETS	(358,391)

From the 2016 audited financial statements which, along with IRS Form 990, are available online at curealz.org.

12,257,906

\$11,899,515

HIGHLIGHTS

Events, press coverage and new partnerships all helped to put Cure Alzheimer's Fund in the spotlight in 2016—and share the message of the importance of research with new audiences.



Annual Symposium

Hundreds of people came together for our 6th annual symposium, held at the Boston Public Library. Rudy Tanzi, Ph.D., Beth Stevens, Ph.D., and Murali Doraiswamy, M.D., each presented on their research.

caringkind

In April, Cure Alzheimer's
Fund created an alliance
with CaringKind, formerly the
Alzheimer's Association, New York
City Chapter. Through this new
relationship, individuals expressing
an interest to CaringKind about
Alzheimer's research now will have
access to the latest information and
resources from CureAlz. Similarly,
CaringKind will ensure CureAlz
and its supporters have access to
critical, state-of-the-art caregiving
services and programs.

Harvard Business School Alumni Reunite

Henry McCance and Jeff Morby, Co-Chairmen and Co-Founders of Cure Alzheimer's Fund and Harvard Business School (HBS) alumni, had their

respective 50th and 55th reunions in June. McCance and Morby each spoke in front of members of their own class and other alumni about the work of Cure Alzheimer's Fund and the importance of research.



Forbes 12 Days of Giving

In December, Forbes.com featured Cure Alzheimer's Fund as part of its annual "12 Days of Charitable Giving" feature. The piece brought in many donations and helped to highlight

the importance of research in the fight against the disease.



Move For Minds


On May 21st, Cure Alzheimer's Fund partnered with Maria Shriver and

Equinox Sports
Clubs for Move For
Minds, an event
that brought women
and men together
to exercise, learn
and raise money for
brain research. The
event raised more
than \$236,000 nationwide.



Co-Funding Research with Rotary

Cure Alzheimer's Fund and Rotary joined forces this fall to fund research into why women are more likely to develop Alzheimer's disease than men.



Before I Forget

Model and restaurateur Barbara "B." Smith now is facing the biggest challenge of her life: early-onset Alzheimer's disease. B. and her husband, Dan Gasby, are going public with their fight—they have written the book "Before I Forget," and are advocating for scientific research through organizations like Cure Alzheimer's Fund.



THANK YOU TO OUR HEROES

Your passion, your energy and your generosity are an inspiration to all of us to work even harder to end this terrible disease. Thank you all for your leadership and support.

Running 4 Answers

"We did it! In 2016, we brought our seven-year



total donations to a quarter of a million dollars! We're looking forward to the next quarter-million."

Carolyn Mastrangelo and Barbara Geiger

Bowling Night

"Alzheimer's affects so many families guys on our job, friends and people in our community. This bowling night is our way of pulling



the community together for a fun night of fundraising and giving back. Any dollar, any penny raised that can get us closer to a cure... well, 'nuff said."

- Lieutenant Ralph Blight, Quincy Fire Fighters IAFF Local 792

Hay Harbor Tennis Tournament

"This terrible disease has impacted so many of us. Cure Alzheimer's Fund is a groundbreaking organization

that is making huge strides, and we are so proud to support it—now for 10 years running."

Diana Fiske



A Ride to Never Forget

"We started with our rear wheels in the Atlantic and dipped our fronts in the Pacific. Thanks to all

who supported and followed us and Cure Alzheimer's Fund as we took on this incredible journey. It was a ride to never forget!"

 Sloan Meadows, Zach Browning and Meadows Farms garden centers



Fashion Show and Golf Tournament

"Our mission is to raise money and awareness to cure Alzheimer's and support families affected by the disease by providing resources and guidance throughout their journey."

Bruce and Gregg Johnson, David K.Johnson Foundation





Rick Sharp Golf Classic

"Rick was committed to finding an Alzheimer's cure, for the benefit of society and our family. He was all in with everything he did, and I see that same passionate approach with Cure Alzheimer Fund's cutting-edge research."















IN HONOR AND IN MEMORY

Cure Alzheimer's Fund receives many gifts in honor or in memory of those with Alzheimer's disease from family and friends. Every day, we are reminded of the scale of this terrible disease and the need to continue to fund breakthrough research.

If you would like to designate a memorial gift, you can do so on our website, by mail or by telephone, and we will gratefully acknowledge each gift by notifying the individuals you have designated. We will do so without disclosing the amount of the donation. At your request, we also will publish memorial photos we receive to the "In Memory" section of our website at www.curealz.org/our-community.

If you have any questions about our *In Memory* program, please contact Laurel Lyle, Director of Fundraising Programs, at **LLyle@curealz.org** or **781-237-3800**.













JOIN OUR EFFORT

Cure Alzheimer's Fund believes it is imperative to focus on and fund research that is innovative, collaborative and results oriented. The research we have funded has provided for tremendous advancements in understanding Alzheimer's disease and the search for a cure. But there is much more work to be done.

We invite you to join our ongoing efforts to support the most promising and productive research to end Alzheimer's disease.

To make a gift, or for ways to give, please visit our website: www.curealz.org/donate.

Or call: 877-CURE-ALZ (287-3259).

Thank you.

CHARITY DESIGNATION

Cure Alzheimer's Fund is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-239-6428.









BOARD OF DIRECTORS & ADMINISTRATION

Cure Alzheimer's Fund is governed by a Board of Directors, administered by a small, full-time staff and guided scientifically by a Research Consortium. A Scientific Advisory Board audits the research program to make sure it is consistent with the objectives of the foundation. To read the biographies of our Board members and staff, please visit **CureAlz.org/about/people.**

BOARD OF DIRECTORS



Jeffrey L. Morby
Co-Chairman of Cure Alzheimer's Fund Board of Directors
Founding Board Member
Former Vice-Chairman of Mellon Bank, President of Mellon Bank Europe
Chairman of the Morby Family Charitable Foundation



Henry F. McCance
Co-Chairman of Cure Alzheimer's Fund Board of Directors
Founding Board Member
Chairman Emeritus of Greylock Partners
Trustee of the McCance Family Foundation



Robert F. Greenhill Chairman and Founder Greenhill & Company



Sherry Sharp
Christian Writer
President and Director of The Sharp Foundation
Director of Sweet Monday Ministry



Jacqueline C. MorbyFounding Board Member
Senior Advisor of TA Associates



Matthew Szulik
Treasurer of Cure Alzheimer's Fund
Chairman of the Szulik Family Foundation
Former Chairman, CEO and President of Red Hat Inc.



Phyllis Rappaport
Founding Board Member
Chair of the Phyllis and Jerome Lyle Rappaport Charitable Foundation
Director of New Boston Fund, Inc.

ADMINISTRATION



Timothy W. ArmourPresident & CEO
Board Member



Barbara ChambersSenior Engagement
Officer



Sally Rosenfield Senior Vice President



Connor SwanDevelopment Associate



Madeleine Adelson Marketing Manager



Laurel Lyle
Director of
Fundraising Programs



John P. Slattery Jr. Senior Vice President, Development



Cindy Turner Bookkeeper



Joyce Cantow Accounting Assistant



Jessica Mutch Chief Financial Officer



Meg Smith Senior Vice President, Research Management Secretary of the Board



Dorothy VacaroGift Processing

Report design: Winking Fish Copy editor: Colleen O'Neill



Main Office

34 Washington St., Suite 200 Wellesley Hills, MA 02481 Phone: (781) 237-3800 Fax: (781) 658-2399 info@curealz.org

Office of the Co-Chairman

Centre City Tower 650 Smithfield St., Suite 2015 Pittsburgh, PA 15222 Phone: (412) 261-2785

Cure Alzheimer's Fund is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-239-6428.